Navigation Links
Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
Date:5/8/2013

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "should," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding:  the Special Protocol Assessment, or SPA, and the protocol for the Contrave® cardiovascular outcomes trial, or Light Study; the potential for, and timing of, the accrual and adjudication of MACE; the expected retention rate for patients in the Light Study; the probability of success of the Light Study; the potential for, and timing of, resubmission and approval of a NDA for Contrave based on interim results of the Light Study; the possibility of resubmitting the Contrave NDA with the independent DMC report on the interim analysis and without the clinical study report for the interim analysis; the potential to accelerate the timing of the review of the Contrave NDA; the safety and effectiveness of Contrave; the potential for past Contrave clinical trials to predict the outcome of future Contrave clinical trials; the potential to enter into a collaborative partnership to fund Phase III development and, if approved, commercialization of Empatic™; the potential for the FDA to approve an NDA for Empatic without requiring data from a cardiovascular outcomes trial in addition to the data obtained from the Light Study; and the use of pharmacotherapy to treat obesity. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ materially from those expressed or implied in this release due to the risk and uncertainties inherent in the Orex
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Orexigen Therapeutics to Present at Upcoming Conferences
2. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
3. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
5. Nile Therapeutics Reports 2011 Third Quarter Financial Results
6. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
7. Fate Therapeutics Strengthens Its iPSC Platform
8. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
9. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
10. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
11. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... group leader Yung-Eun Sung has announced that they ... nitrogen-doped graphenes which can be applied as high ... Yung-Eun Sung is both a group leader at ... Basic Science* (IBS) and a professor at the ... significance with regards to the development of relative ...
(Date:7/24/2014)... natural and synthetic processes prefer to settle into ... energyit is within the realm of non-equilibrium conditions ... changes in energy and phases, such as temperature ... allow humans to regulate their body temperature, airplanes ... seismic activity. , But even though these ...
(Date:7/24/2014)... 2014 Your cell phone may ... lithium-ion battery storage capacity. , New research indicates ... model created at Lawrence Livermore National Laboratory ... how carbon components will perform as electrodes. , ... urgent need for higher-performance batteries. Several key characteristics ...
(Date:7/24/2014)... Francisco, CA (PRWEB) July 24, 2014 ... to be semi-finalists in Livestrong’s Big C Competition. Out ... Health are each headed to the semi-final round. In ... Livestrong’s exclusive three-month accelerator program, complete with mentoring from ... , As part of the angelMD commitment to ...
Breaking Biology Technology:New approach to form non-equilibrium structures 2Getting More Life out of Lithium-ion Batteries 23 angelMD Startups Make Livestrong Big C Semi-finals 2
... June 17, 2011 After the Strategic Meeting with ... Combined Fuels Inc (OTC:PRCF) and its Principal Company Euro-Pacific ... and CEO announced the company,s readiness to Distribute Internationally ... in the world which as of now are the ...
... SUNNYVALE, Calif., June 17, 2011 Pharmacyclics, Inc. (Nasdaq: ... entered into stock purchase agreements with various institutional investors ... of its common stock in a registered direct offering ... 16, 2011.  Gross proceeds of the offering, before deducting ...
... ResearchDx, LLC of Irvine, California today announced ...  ResearchDx and CompanDX have forged a unique partnership ... deliver novel molecular diagnostic tests for clients in ... platform to deliver small composite biomarker signatures from ...
Cached Biology Technology:Most Expensive Teas in the World Worth US$44,500 per 4 Ounces Each are Positioned for International Distribution Says Protein Reactor Combined Fuels Inc (OTC: PRCF) Founder Chairman and CEO Nestor C. Buenaflor 2Most Expensive Teas in the World Worth US$44,500 per 4 Ounces Each are Positioned for International Distribution Says Protein Reactor Combined Fuels Inc (OTC: PRCF) Founder Chairman and CEO Nestor C. Buenaflor 3Pharmacyclics Announces Results of Registered Direct Offering 2Pharmacyclics Announces Results of Registered Direct Offering 3ResearchDx and CompanDX Announce Strategic Partnership 2
(Date:7/24/2014)... by 45% on average over a 35 year period ... on the impact of humans on declining animal numbers. ... such as insects, spiders, crustaceans, slugs and worms bring ... for crops, decomposition for nutrient cycling, water filtration and ... and led by UCL, Stanford and UCSB, focused ...
(Date:7/24/2014)... study has identified two factors that characterize sustainable ... production of highly qualified physics teachers. Specifically, one ... physics teacher education in combination with institutional motivation ... viable. Science, Technology, Engineering and Math (STEM) teacher ... study points the way for institutions seeking to ...
(Date:7/24/2014)... the product of 3.5 billion years of evolutionary trial ... life. But it may be reaching a tipping point. ... analysis of data published in Science , an ... decline of animals is contributing to what appears to ... biological extinction event. , Since 1500, more than 320 ...
Breaking Biology News(10 mins):Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3Creating sustainable STEM teacher preparation programs 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3
... it,s good for your baby, according to a new study ... published in Applied and Environmental Microbiology , is the ... sulfide and ajoene that significantly reduce the contamination risk ... infant formula powder. The discovery could make the product ...
... a variety of methods to spread their seeds, including gravity, ... of the mushrooms, whose spores also need to be strewn ... have long thought that the spores produced by a mushroom,s ... problem with that notion, said Emilie Dressaire, a professor of ...
... water chemistry to nutrient enrichment to acid rain and ... Peter Tobiessen is designed for the non-scientist. "Ultimately, ... better understand the dynamics within these complex ecosystems," Tobiessen ... beautiful ecosystems, the deeper appreciation we will have for ...
Cached Biology News:The mushrooms, my friend, are blowing in the wind... 2
... The M-840 HEXALIGHT robot is based on ... (PKM) over more than a decade. PI ... for mirror and antenna adjustments over wide ... provides six degrees of freedom with 3 ...
... can provide custom microplate coating using advanced automated high throughput ... plate formats. We can also accommodate virtually any lot size ... L):, , 8 and ... microplate, 384 well microplate, ...
... insert sequencing service for large insert vectors ... Agencourt utilizes unique library construction techniques to ... several features that allow Agencourt to provide ... including our patented magnetic bead-based SPRI technology, ...
...
Biology Products: